47 results about "Glycated hemoglobin" patented technology

The invention relates to a probiotic preparation containing a BL11 strain and capable of improving obesity-related metabolism and senescence indexes of middle-aged and elderly people and application of the probiotic preparation. The strain in the probiotic preparation is composed of a bifidobacterium longum subsp. Longum BL11 strain and a pediococcus acidilactici PA53 strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect in the aspect of improving obesity-related metabolic indexes, which is specifically embodied in that: the weight increase and body fat rate of mice fed with high fat diet can be reduced; the low-density lipoprotein level, the total cholesterol level and the triglyceride level are reduced, and the high-density lipoprotein level is improved; fasting blood-glucose, glycosylated hemoglobin level and insulin resistance index are reduced; chronic inflammation is relieved; meanwhile, the composition also has excellent performance in the aspect of improving senescence-related indexes, the content of malondialdehyde in serum can be reduced, the activity of superoxide dismutase and glutathione peroxidase can be improved, and the activity of telomerase can be improved.

The invention relates to the technical field of spectral component measurement, in particular to a high performance liquid chromatography detection method of glycosylated hemoglobin for a diabetic pregnant woman. According to the method, high performance liquid chromatograms at different temperatures are obtained, the chromatograms are processed through EMD mode decomposition, screening is carried out according to peak value characteristics, and the IMF component of the hemoglobin component is determined. Matching the IMF components of the hemoglobin components at different temperatures, and obtaining the hemoglobin type of each IMF component of the hemoglobin components according to the obtained temperature matching components and the retention time of the middle components. And counting the content of each hemoglobin type at all temperatures to obtain the content of each hemoglobin type in the blood sample. According to the method, errors in detection are eliminated through chromatographic detection and data statistics, and a more accurate detection result of glycosylated hemoglobin of a diabetic pregnant woman is obtained.

The present disclosure relates to systems and methods for measuring glycated A1c hemoglobin. A glycated hemoglobin level measuring system includes a sample testing apparatus having a microchannel that compresses a blood sample traveling through, a first pair of electrodes coupled to the microchannel, and a second pair of electrodes coupled to the microchannel. The glycated hemoglobin level measuring system further includes an analysis apparatus having sensors coupled to the first and second pairs of electrodes and configured to calculate a travel time taken by a red blood cell to pass through the first and second pairs of electrodes. The glycated hemoglobin level measuring system can use the travel time to measure a rigidity of the red blood cells and the corresponding glycated hemoglobin level.

The utility model relates to the technical field of medical detection devices, and discloses a glycosylated hemoglobin detection device, which comprises a sampling mechanism, a detection mechanism and a control mechanism, the sampling mechanism comprises an injection pump set, a sampling needle and a sampling valve, the sampling valve is a six-way sampling valve, the injection pump set is connected with a first port of the sampling valve, and the sampling needle is connected with a second port of the sampling valve; the separation mechanism comprises an eluent group, a mixer and a chromatographic separator, the eluent group is connected with a fifth port of the sample injection valve, the chromatographic separator is connected with a sixth port of the sample injection valve, and two ends of the mixer are connected with a third port and a fourth port of the sample injection valve; the inspection mechanism comprises a filter and an inspector, the filter is arranged between the mixer and the chromatographic separator, and the inspector is connected with the chromatographic separator. According to the utility model, the glycosylated hemoglobin can be rapidly and accurately detected through an accurate sample introduction and separation mechanism, so that the detection efficiency is improved. The automation degree of the detection process is high, the requirement for manual operation is reduced, and the possibility of human errors is reduced.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.

A method of calculating at least one physiological parameter using a reticulocyte production index (RPI) value can include: measuring a plurality of first glucose levels over a first time period; measuring a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; measuring the RPI value; calculating a red blood cell elimination constant (kage) based on the RPI value; and calculating the at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (kgly), a red blood cell generation rate constant (kgen), and an apparent glycation constant (K), based on (1) the plurality of first glucose levels, (2) the first HbA1c level, and (3) the kage. Further, one or more related analyses (e.g., personalized-target glucose range, personalized-target average glucose, cHbA1c, and the like) can be estimated and / or adjusted based on the at least one physiological parameter.

According to the human body metabolic system physiological age prediction method based on machine learning, six blood detection indexes including total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood sugar, glycosylated hemoglobin and triglyceride which are closely related to a metabolic system are collected in a targeted manner; and respectively carrying out computer model modeling on male and female data according to the physical examination data of the metabolic system, and constructing a computer model for predicting the physiological age of the human metabolic system of the male and female so as to evaluate the physiological age of the human metabolic system of individuals with different genders. According to the human body metabolism system physiological age prediction method based on machine learning, core data only uses blood data indexes related to the human body metabolism system for modeling, the physiological age model of the human body metabolism system is constructed, and the physiological age of the human body metabolism system can be evaluated in a targeted mode; modeling is carried out for men and women based on data differences of genders of men and women, so that the prediction result is more accurate.

The present invention discloses an immunochromatographic test strip for glycated hemoglobin, which comprises a base plate, a sample pad, a conjugation pad, a reaction membrane, and an absorbent paper pad; the conjugation pad contains an immunoprobe; the immunoprobe is an HbA1c antibody labeled with CIS / ZnS core / shell quantum dot fluorescent microspheres. The immunochromatographic test strip for glycated hemoglobin of the present invention utilizes the rapid and simple advantages of immunochromatographic technology coupled with the easy excitation, strong luminescence, and strong photostability of quantum dots. Through an evaporation swelling method and innovative reaction principles and synthesis steps, novel quantum dot fluorescent microspheres are prepared. Furthermore, the novel quantum dot fluorescent microspheres are uniquely used as markers to prepare immunoprobes through the EDC method. On this basis, an HbA1c chromatography test strip is constructed, and the purpose of quantifying HbA1c is achieved by detecting the fluorescent signal of the test strip.

Systems and methods are provided for providing diabetes patient treatment guidance for a patient in which a biochemical data set is obtained. The biochemical data set comprises test results from a single blood draw of the patient including at least three measurements selected from the set: a high-sensitivity c-reactive protein test, an adiponectin level test, an intact proinsulin level test, an insulin level test, a C-peptide test, a HbA1c test, and an eGFR level test. A demographic data set for the patient is also obtained that comprises the patient's gender and diabetes stage. The biochemical data set and demographic data set is run against one or more rules to determine a first patient therapy pattern. Then, a report is prepared based on an identity of the first therapy patient pattern. The report sets priorities among intervention classes for the patient based on the identity of the first patient pattern.

This invention provides a hypoglycemic subspecies of Bifidobacterium animalis (Liver) and its applications. The Bifidobacterium animalis (Liver) subspecies is named Tianshan-1 and is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 35821 on September 5, 2025. Cell experiments show that Tianshan-1 significantly promotes the secretion of GLP-1 from human colorectal adenocarcinoma cells NCI-H716 and upregulates GCG gene expression levels. Animal experiments confirm that this strain significantly increases serum GLP-1 concentration in diabetic mice and reduces fasting blood glucose and glycated hemoglobin levels, with no significant difference in hypoglycemic effect compared to the positive control. This strain is a food-grade safe probiotic with a clear mechanism of action and stable effects, providing a safe, long-lasting, and industrially viable new probiotic resource for diabetes prevention and treatment, with broad application prospects.

The invention relates to the technical field of diabetes medicine development, in particular to a three-target-point active peptide, a fusion protein and application of the three-target-point active peptide and the fusion protein. The invention provides an active peptide and a fusion protein with GLP-1 / GIP / GCG three targets, and test results show that the active peptide and the fusion protein both have GLP-1 / GIP / GCG three-target activity, can significantly improve glucose tolerance and insulin tolerance, can significantly reduce the proportion of glycosylated hemoglobin, and can significantly improve the activity of the GLP-1 / GIP / GCG three targets. Wide application prospects are realized in the fields of blood glucose control and / or metabolic disease prevention and treatment.

The invention discloses a diabetes mellitus personalized nursing intelligent medical management system based on an AI algorithm, and belongs to the crossing field of intelligent medical treatment and artificial intelligence. According to the system, a three-layer dynamic coupling architecture of data perception, AI decision making and interactive execution is adopted, algorithms such as a space-time diagram convolutional network, hierarchical reinforcement learning and differential privacy federated learning are fused, and multi-source data intelligent fusion, 72-hour complication prospective early warning, minute-level personalized nursing scheme generation and model adaptive evolution are achieved. Clinical verification shows that the system can remarkably reduce the glycosylated hemoglobin level of a patient, improve the blood glucose standard-reaching rate and the scheme execution rate, reduce diabetes related emergency treatment and relieve the workload of medical care, and is low in deployment cost, convenient to operate, high in privacy, suitable for management of various diabetes mellitus and capable of being expanded to other chronic diseases, such as diabetes mellitus, diabetes mellitus, diabetes mellitus and diabetes mellitus. The system is suitable for multiple scenes such as medical institutions, communities and families.

Disclosed herein are compositions and methods for treating diabetes wherein the compositions comprise GLP-1 agonists. The disclosed compositions are also effective for reducing body weight and improving triglyceride and cholesterol levels. Disclosed herein are methods for treating type-2 diabetes in a subject, for lowering a subject's A1C, for lowering the body mass of a subject, and for regulating the incretin hormone levels of a subject.

Provided is a measurement method for HbA1c that includes a step for calculating a peak area for unstable glycosylated hemoglobin E included in peaks for unstable glycosylated hemoglobin A1c or stable glycosylated hemoglobin A1c from a peak area for stable glycosylated hemoglobin E, a peak area for unstable glycosylated hemoglobin A1c, and a peak area for stable glycosylated hemoglobin A1c. The measurement method thereby makes it possible to accurately analyze HbA1c concentration even when the potential effect of unstable glycosylated hemoglobin E is high.

The glycosylated hemoglobin quantitative detection and analysis device comprises a machine body, a detection area and a display control area are preset on the left side and the right side of the machine body, a stand column is installed in the detection area, the stand column is sleeved with a lower ring plate, and the stand column over the lower ring plate is sleeved with an upper ring plate; a plurality of mutually aligned placing holes are formed in the upper ring plate and the lower ring plate, a concave cavity in the radial direction is formed in the part, between the upper ring plate and the lower ring plate, of the stand column, a second movable plate and a first movable plate are installed on the concave cavity and the side face opposite to the concave cavity respectively, and bayonets aligned with the placing holes are formed in the second movable plate and the first movable plate; and an excitation light source and a photoelectric detector which are opposite to each other are respectively arranged in the movable plate II and the movable plate I. A sample is placed in the placing holes of the upper ring plate and the lower ring plate, during detection, the first movable plate and the second movable plate actively approach and surround the sample, a good internal light shielding environment is obtained, and external light is difficult to enter the interior to affect a detection result.

The invention relates to lactobacillus paracasei KXW5 with a hypoglycemic function and application thereof, and belongs to the technical field of microorganisms. In order to excavate a microecological preparation for treating hyperglycemia-related diseases, a strain of lactobacillus paracasei KXW5 is separated, and in-vivo and in-vitro experiments prove that the strain has remarkable blood sugar reducing capacity, including promoting proliferation of high-glucose-induced INS-1 cells, improving the relative expression quantity of MafA genes in the high-glucose-induced INS-1 cells and improving the blood sugar reducing capacity. The fasting blood glucose level, postprandial blood glucose level, insulin resistance level, glycosylated hemoglobin level, liver copper ion level and the expression level of copper death related genes FDX1 and DLAT in the liver of the type II diabetes mellitus patient are reduced, and the oral glucose tolerance of the type II diabetes mellitus patient is enhanced. The strain KXW5 provided by the invention can be used for preparing medicines for reducing blood sugar and preventing and / or treating diabetes mellitus or health-care foods for assisting in reducing blood sugar, and opens up a new way for preventing and treating diabetes mellitus.

Disclosed herein are compositions and methods for treating diabetes wherein the compositions comprise GLP-1 agonists. The disclosed compositions are also effective for reducing body weight and improving triglyceride and cholesterol levels. Disclosed herein are methods for treating type-2 diabetes in a subject, for lowering a subject's A1C, for lowering the body mass of a subject, and for regulating the incretin hormone levels of a subject.

The invention discloses a deep learning personalized nutrition recommendation method and system based on a user portrait, and the method comprises the steps: collecting user physiological indexes, diet behaviors and environment parameters through a wearable device, intelligent tableware and an environment sensor, and obtaining collection data; inputting the collected data into a dynamic causal time sequence model, calculating the time-varying causal intensity of a diet event and a physiological index by adopting a convergent cross-mapping algorithm, and dynamically adjusting the length of a sliding window according to the maximum physiological response delay, a diabetes risk factor and a glycosylated hemoglobin deviation value; and extracting a user portrait vector containing metabolic phase shift through a bidirectional gating network. According to the method, a dynamic nutrition recommendation system of metabolism perception is constructed, and the core problems of dynamic metabolism response modeling and abnormal state real-time regulation and control are solved through a multi-modal data fusion and pathology-driven adaptive learning mechanism.

Aspects of the present disclosure include methods for treating a subject having a metabolic disorder by neuromodulation. Methods according to certain embodiments include applying electrical stimulation to the spinal cord of a subject (e.g., a subject diagnosed as having or determined to have diabetes or prediabetes) in a manner sufficient to treat at least one symptom of the metabolic disorder in the subject. In some embodiments, neuromodulation is sufficient to treat one or more symptoms of diabetes or prediabetes such as fasting plasma glucose concentration, non-fasting plasma glucose concentration, elevated hbA1c, glucose tolerance and insulin secretion by the subject. Systems having one or more electrodes configured for applying electrical stimulation to the spinal cord of the subject suitable for practicing the subject methods are also described.

The invention relates to the technical field of gestational diabetes mellitus detection, and discloses a gestational diabetes mellitus serum marker detection data analysis system. The system comprises a serum biochemical data acquisition module, a detection device is used for acquiring a serum sample of a pregnant woman, and a serum biochemical data set containing blood sugar concentration, insulin level and glycosylated hemoglobin indexes is constructed; a multi-dimensional index integration module combines a historical detection time sequence and the physiological parameter information of the current detection time period to generate an integrated data set containing time dimension correlation features; the abnormal risk analysis module processes the time dimension correlation features in the integrated data set, and calculates the risk deviation value of gestational diabetes in the current detection period; when the risk deviation value is abnormal, the risk grading module generates a plurality of candidate intervention classification schemes based on the serum biochemical data set, and outputs the intervention influence degree of each candidate scheme; and an intervention scheme generation module screens the candidate scheme with the lowest intervention influence degree and generates an optimal intervention classification scheme in the current detection time period.

A method of calculating at least one physiological parameter using a reticulocyte production index (RPI) value can include: measuring a plurality of first glucose levels over a first time period; measuring a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; measuring the RPI value; calculating a red blood cell elimination constant (kage) based on the RPI value; and calculating the at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (kgly), a red blood cell generation rate constant (kgen), and an apparent glycation constant (K), based on (1) the plurality of first glucose levels, (2) the first HbA1c level, and (3) the kage. Further, one or more related analyses (e.g., personalized-target glucose range, personalized-target average glucose, cHbA1c, and the like) can be estimated and / or adjusted based on the at least one physiological parameter.

The invention relates to a method and system for predicting the anxiety mood prevalence rate of a diabetic child patient, and belongs to the field of artificial intelligence prediction. According to the method, multi-dimensional clinical data such as demographic data, treatment modes, management behaviors and metabolic indexes of diabetic children are collected, evaluation results of a children anxiety mood disorder screening table (SCARED) are combined, single-factor analysis, correlation analysis and multi-factor Logistic regression analysis are carried out, and an anxiety mood prediction model is constructed. The model takes age, an insulin treatment mode and glycosylated hemoglobin as core variables, and can accurately predict the anxiety risk of a child patient. The system comprises a data acquisition module, a psychological assessment module, an analysis modeling module, a risk prediction module and a report generation module, and realizes automatic data integration, model construction and individual intervention suggestion output. Clinical verification shows that the model prediction efficiency is excellent, and the method has good clinical application value and is beneficial to early recognition and intervention of anxiety mood of diabetic children and improvement of physical and psychological health and disease management quality of the diabetic children.

A method of data analysis is provided. The method is used for finding a long-term trend of blood glucose concentration. The method builds a model for estimating long-term glycemic variability and long-term blood glucose trajectory. Based on single-erythrocyte-level glycated hemoglobin distribution, the glycemic variability is analyzed. A first analysis method is to give a number. The number shows the level of the historical glycemic variabilities. A second analysis method is to restore the blood glucose trajectory over the past 20 weeks. Based on the single-erythrocyte-level glycated hemoglobin distribution, the present invention easily assesses blood-glucose-related clinical information for about 150 days. Hence, an important complement is obtained for diabetes-related or glucose-monitoring-related clinical applications.

The present invention provides a hemp seed protein peptide for reducing blood sugar and regulating glucose metabolism, its preparation method and application, belonging to the technical field of functional active peptides, and comprising the following steps: The hemp seeds are subjected to low-temperature supersonic fluid pulverization, the pulverized hemp seeds are subjected to enzymatic pretreatment, compound protease is added for enzymatic hydrolysis, PNGaseF enzyme is added for further enzymatic hydrolysis to obtain an enzymatic hydrolysate, the supernatant of the enzymatic hydrolysis is enriched by membrane ultrafiltration interception, and then concentrated, dried and sterilized by tangential flow filtration to obtain the hemp seed protein peptide. The new hemp seed protein peptide in the present invention has been experimentally proven to have the following remarkable effects: It can significantly reduce the fasting blood sugar level and relieve the discomfort symptoms such as thirst, polydipsia, polyuria and fatigue caused by hyperglycemia; It can significantly relieve the symptoms of glucose intolerance and insulin resistance caused by hyperglycemia and reduce the risk of type 2 diabetes; It can significantly reduce the levels of fasting serum insulin and glycated hemoglobin and increase the level of serum GLP-1.

The present invention discloses a biomarker and a therapeutic target for type 2 diabetes and an application method of enteromorpha oligosaccharides. In this scheme, OASL protein or its encoding gene or transcription product is used as a biomarker and a therapeutic target for type 2 diabetes caused by a high-sugar and high-fat diet; the biomarker is detected by specifically amplifying RNA transcribed from the OASL gene using RT-qPCR technology; for the target, the present invention also develops an enteromorpha oligosaccharide drug, which can specifically increase the expression of OASL protein and improve fasting blood sugar, insulin and glycosylated hemoglobin levels, and is of great significance for the rapid identification and treatment of type 2 diabetes.

Provided is a glycated hemoglobin measuring apparatus. The apparatus for measuring glycated hemoglobin includes a cartridge for receiving blood and a plurality of chemicals, a rotating tray for rotating the cartridge, wherein the cartridge is disposed inside the rotating tray, a driver having a nozzle disposed above the cartridge and movable in a vertical direction, and a measurement unit located above the cartridge and measuring glycated hemoglobin of the blood, wherein the driver sucks at least one of the blood, the plurality of chemicals, and mixed solution of the blood and the plurality of chemicals into the nozzle or discharges the sucked at least one into the cartridge such that the blood is chemically treated through the plurality of chemicals.

The invention relates to lactobacillus rhamnosus KXW1 with a hypoglycemic function and application of the lactobacillus rhamnosus KXW1, and belongs to the technical field of microorganisms. In order to excavate a microecological preparation for treating hyperglycemia-related diseases, a strain of lactobacillus rhamnosus KXW1 is separated, and in-vivo and in-vitro experiments prove that the strain has remarkable blood sugar reducing capacity, including promoting proliferation of high-glucose-induced INS-1 cells and increasing the relative expression quantity of MafA genes in the high-glucose-induced INS-1 cells, so that the hyperglycemia-related diseases can be treated. The fasting blood glucose level, postprandial blood glucose level, insulin resistance level, glycosylated hemoglobin level, liver copper ion level and the expression level of copper death related genes FDX1 and DLAT in the liver of the type II diabetes mellitus patient are reduced, and the oral glucose tolerance of the type II diabetes mellitus patient is enhanced. The strain KXW1 provided by the invention can be used for preparing medicines for reducing blood sugar and preventing and / or treating diabetes mellitus or health-care foods for assisting in reducing blood sugar, and opens up a new way for preventing and treating diabetes mellitus.

Disclosed herein are methods of treating diabetic cardiomyopathy (DbCM) using an aldose reductase inhibitor, and methods of inhibiting decline in cardiac functional capacity and / or progression to overt heart failure in a subject with DbCM using an aldose reductase inhibitor. Also disclosed are aldose reductase inhibitors and compositions thereof for use in treating diabetic cardiomyopathy (DbCM), or inhibiting decline in cardiac functional capacity and / or progression to overt heart failure in a subject with DbCM. Subjects treated by the methods and uses are not administered a sodium-glucose cotransporter-2 (SGLT2) inhibitor and / or have an HbA1C value greater than 8.5%.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.

The present invention relates to an optical sensor and a wearable device comprising the same for non-invasively determining a concentration of blood components, for example, blood glucose and glycated hemoglobin levels. The optical sensor comprises an emitter configured to emit short-wave infrared (SWIR) radiation, an insulator with a channel transparent to the SWIR radiation, the emitter being disposed on top of the insulator and configured to emit the radiation into a biological tissue through the transparent channel, an optical concentrator made from a material with a refractive index of 1.7 or more, and a photodetector disposed in an upper part of the optical concentrator. The invention provides the possibility of non-invasive, instant or continuously monitoring of blood glucose and glycated hemoglobin levels. 2 indep. claims and 13 dep. claims, 15 figs., 2 tables.